ÍNDEX Main figures in Biomedicine

Spain

Catalonia

Biopol’H

Biopol’H Scientific and Health Park

Biopol’H Business Park area

The Bioincubator of Biopol’H

Alliances and collaboration agreements

2

5

8

9

12

13

14

Barcelona Bellvitge Biopol ICO campus hospitals cancer knowledge centers HPVclinics development business companies Catalonia biotechnology Spain education Hospitalet de Llobregat HUB innovation spin-off IDIBELL oncology medicine HUBc industry institutions promotion university healthcare production research patients projects health services lifeTechnology transplants network science

Spain

> Bioinformatics> Advanced Terapies> Animal Health Production> Nanomedicine> Personalized Medicine> Anti-aging Medicine

> Generic and Biosimilar Drugs> Oncology > Clinical Trials> Food Quality and Biosecurity> Biopharming> Health Technologies

Spain strongly pledges its commitment to R & D, promoting the knowledge economy and innovation as the driving forces of wealth production. This country has a growing network of centres and institutions dedicated to the promotion of research; one of the most outstanding is the Spanish National Research Council (CSIC), which ranges from basic research to knowledge transfer to the productive sector.

In 2010, the CSIC invested € 190,835,309.26 in Biology and Biomedicine, by far the largest allocation of its budget. Nine researchers from spanish research centres were awarded in the announcement of the European Research Council Advanced Grant Life Sciences in 2011. In Spain, we are investing in the develop-ment and consolidation of several biotechnology areas:

The Spanish biotechnology industry is an emerging industry where the creation of business has in-creased significantly in recent years. In 2009 there were 1,095 companies related to technology activities and 399 strictly biotech companies.

There is a strong spin-off culture, since every year between ten and twelve new companies are created from Public Institutions. It is estimated that in 2012, directly and indirectly, biotechnology will involve 1.6% of Spanish GDP. There are various factors driving this trend:

IntegratedHealth System

InternationalCooperation

Clinical Trials with greaterprofitability

5th Europeanpower in scientific

production

Highlytrained

professionals

Leadinginfraestructurefor innovation

Leader country inAgrobiotechnology

Over 450pharmaceutical

companies

Exponential growth of Science and

Technology Parks

9th worldpower inscientific

production

Great publicsupport forcompanies

TranslationalMedicine

International cooperation: 143 alliances between Spanish and international companies in 2010, 18% from

Europe and 6% from the U.S.

Clinical trials with greater profitability: about 3,000 studies are carried out in Spain –it is the 5th country

of the EU-27 with more clinical trials. Tthe cost of a clinical trial per patient is 30% lower than in other markets

like the U.S.

A powerful Spanish pharmaceutical industry: which has over 450 pharmaceutical companies and repre-

sents 20.3% of the total private investment in R & D of Spain

Strong basic science: as far as scientific production is concerned, Spain ranks as the 9th world power

and the 5th European powerIntegrated Health System: with a comprehensive network of 900 hospitals, public and private.

Emerging biotechnology industry: which has great public support for companiesLeading infrastructure for innovation: exponential growth of Science and Technology Parks, Research Centres and Institutes of TechnologyHighly trained professionals: with a surplus of talent to be exploited in competitive and innovative projects

The complete turnover of the biotechnology business activity was almost €4.500M in 2009, generating employment for 12,600 people – including companies of Biotechnology (EB) and the companies of industry, commerce and services of in Biotechnology (EIB) –.

In 2010 about 550,000 people received treatment with biopharmaceuticals and biotechnological testing is being introduced into the National Health System for the diagnosis of microbiological, cancer, haemato-logical or genetic diseases.

Along with the leading research centres, the Integrated Health System becomes a top-quality system for the development of translational medicine and the discovery of new drugs and advanced therapies.

The scientific production in Life Sciences improved the production of articles of maximum impact significantly throughout 2011, occupying the 5th position in the EU-15.

The number of requested patents kept stable and the volume of R & D agreements between universities and Public Research Entities (OPI) and companies remains in the same level as in 2007.

Another health sector where Spain stands out is trasplants. In 2011 a total of 81,909 transplants had been made in our country. The National Transplant Organization (ONT) has 179 hospitals approved for donations and 43 hospitals licensed to perform transplants distributed around the 17 autonomous communities.

Just to provide some data, 194 heart transplants, 764 liver transplants and 2,063 kidney transplants were performed only in Catalonia in the period between 2008 and 2009. In 2011 the total number of donors in Spain was 1,667 –who were living or asystolic donors. If we break down the total number of transplants performed in Spain by type, the figures are as follows:

51.909 kidney transplants

6.528 heart transplants

1.342 pancreas transplants

19.399 liver transplants

2.702 lung transplants

80 intestine trasplants

Catalonia is currently on the 3rd place of the ranking in scientific excellence among the EU, only behind the Netherlands and Sweden.

The Catalan Bio Region has a bigger concentration in Barcelona’s area, especially around its Metropolitan Area. It has a total number of 1,156 entities, among which there are over 268 enterprises working on red biotechnology –that is, the Health and Life Sciences Biotechnology.

As a whole, the Catalan BioRegion has created jobs for more than 29,000 people –including research staff, associated services, etc. Catalonia houses the 20,5% of all the biotec enterprises established at Spain.

However, if Catalonia’s and Spain’s economical impact is compared, this proportion is oversized because with an ap-proximated annual turnover of €15,600 millions, Catalonia contributes with the 29,4% of the state’s total amount. Also, it is the most dynamical autonomous community, responsible for the creation of the 23% of new biotec in 2010.

All this wealth has been created from local initiative and it is deep-seated on Catalan’s social fabric –as it is proved by the fact that only the 16% of the enterprises from the Catalan BioRegion are multinational’s branches.

Catalonia

350companies70 of them are pharmaceutical, 65 biotech-nological, 123 of innovative medical technol-ogies, and the rest provide support services or are linked to the sector in some way

17science and technology parks13 of them carrying out activities in biotech-nology and biomedicine

12universities10 of them offering studies in Life Sciences and some of the most important internation-al business schools (2 of which rank among the 20 best business schools in the world)

900recognized research groups400 of them working on Life Sciences’ related research

150research centers60 of them carrying out research related to Life Sciences

7/1000researchers7 researchers per 1000 working population

215hospitals13 hospitals with noteworthy research activ-ity out out of 215, 6 of which are among the most productive in Spain in terms of scien-tific output

21csic centerslocated in Catalonia

CataloniaAn autonomous community with a booming biotechnology sector

Catalonia has the largest network of hospitals in Spain. It is the autonomous community with more hospitals and healthcare centres. Renowned for its pioneering research in Oncology – especially for the research and clinical care that takes place in the Catalan Institute of Oncology, which has three venues in Catalan ter-ritory: L’Hospitalet, Girona and Badalona.

The list of TOP-20 Spanish, the ranking of the most prestigious hospitals, is produced every year by the IASIST. The list of the hospitals awarded in the announcement of 2011 includes the following Catalan centres:

Small general hospitals> Sant Bernabé Regional Hospital. Berga> Campdevànol Regional Hospital of Ripollès> Sant Jaume Hospital of Olot

Medium general hospitals> Comprehensive Health Consortium. Centre for Comprehensive Care Dos de Mayo Hospital. Barcelona> Empordà Health Foundation. Figueres> St. Pau and St. Tecla Hospital Foundation. Tarragona

Big general hospitals> Fundación Hospital/Asilo of Granollers> Public Health Consortium of Maresme

Hospitals with benchmark Specializations> Hospital of Sabadell. Health Corporation Parc Taulí> Mútua Terrassa University Hospital > Arnau de Vilanova University Hospital. Lleida

Big hospitals of regional and national benchmark> St. Joan de Déu Health Association – Clinic Hospital of Barcelona> St. Pau Hospital – Puigvert Foundation. Barcelona> Bellvitge University Hospital. L’Hospitalet de Llobregat

Benchmarks of the Nervous System area> Health Consortium of Maresme – Hospital of Mataró> St. Pau and St. Tecla Hospital Foundation. Tarragona

Benchmarks of the Respiratory area> Bellvitge University Hospital. L’Hospitalet de Llobregat

Benchmarks of the Heart area> Hospital of Sabadell. Health Corporation Parc Taulí> Mútua Terrassa University Hospital

Benchmarks of Digestive Surgery> Empordà Health Foundation. Figueres> St. Pau Hospital – Puigvert Foundation. Barcelona

Benchmarks of Traumatology and Orthopaedics> Hospital of Sabadell. Health Corporation Parc Taulí

Benchmarks of Women’s Health> St. Joan de Déu Health Park. Sant Boi de Llobregat> Campdevànol Regional Hospital of Ripollès> Health Foundation of Mollet> Health Consortium of Anoia. Igualada>Hospital of Sabadell. Health Corporation Parc TaulíMútua Terrassa University Hospital

Biopol’HBiopol’H is a hub of innovation constituted by a number of companies, organizations, and public healthcare and research institutions performing closely related activities to share knowledge.

These companies and organizations give a high added value to the scientific and financial district, which goes along Gran Via in Hospitalet, from the Bellvitge University Hospital to the Institute of Legal Medicine. Part of this district are pharmaceutical adn medical devices companies such as Ferrer, Chiesi and Werfen; service companies, training companies (Study Centre Joan XXIII) and engineering companies of high technology competitive value (PROMAUT, Gutmar).

Some of the most important research and health centres in Catalonia are also present, like the Catalan Institute of Oncology, the Bellvitge University Hospital and the Bellvitge Biomedical Research Institute, the Institute for Bioengineering of Catalonia and the Health & Life Sciences Campus (University of Barcelona) as the centre of training and knowledge production. The hub employs 4380 people.

In short, Biopol’H is a cluster of companies and

organizations performing closely related activities in order

to carry out a joint action in search of a collective efficiency.

Chirurgical

Medical

Welfare support

Logistics support

Researchers

Employees of the Biopol’H institutions

Catalan Institute of Oncology (ICO)

Located in the Duran i Reynals Hospital, the Catalan Institute of Oncology (ICO) is the hospital centre in Spain with the highest quality research by its impact factor, normalized by its publications as an institution devoted to health (SCIMAGO SIR World Report 2011). 70% of their articles are published in the most influential scientific journals. As a hospital, it is the 10th best in Spain according to the Ranking Web of World. There are 10 linear accelerators in the premises, the highest amount of Spain.

One of the remarkable projects is the research on Human Papilloma Virus (HPV), developed by Dr Xavier Bosch’s team. This research has taken the organization to lead the creation of an international platform on the vaccine for HPV – which is responsible for cervical cancer. The aim of the International Information Centre on HPV and prevention of cervical cancer – formed by the ICO and the Bill and Melinda Gates Foundation – is to advice the WHO on preventive vaccination against HPV, which can avoid the 70 % of cancer cases.

In particular, it is also worth mentioning the collaboration of the ICO with the WHO in the QUALY programme for the promotion of quality in palliative care; the patient care in Functional Units that comprise differ-ent professionals to jointly evaluate every case that comes to the ICO – to make the decision together about what would be the most appropriate diagnosis and treatment for the patient –, and the advanced radiotherapy and brachytherapy devices of the institute.

HOSPITALS

Hospital Duran i ReynalsHospital Universitari de BellvitgeHospital Moisès BroggiHospital General de L’Hospitalet

80 research groups distributed among three re-search centers

RESEARCH CENTERS

11 companies of health sector, services, training and medical technology

ENTERPRISES

The Health University of Barcelona Campus (HUBc) has been recognized as a Campus of International Excellence (CEI). It comprises 6 hospitals and 4 schools, offers more than 30 degrees and performs 500 clinical trials

Biopol’H Scientific and Health Park

Bellvitge University Hospital (HUB)

The HUB has been given the TOP-20 Hospitals Awards prize for the fourth time, being the winner in the field of Hospital Management. It is a tertiary benchmark centre for Stroke, resistant bone and joint infections in Catalonia and was the first Spanish hospital to perform a partial breast reconstruction via endoscopy, the fourth hospital to do so in the world. The Hospital is a high complexity centre of reference for over 2 million inhabitants.

The HUB pledged its commitment to the Davinci system in interventions of the services of Urology, Gynaecology and General and Digestive Surgery, with some pioneering operations of the whole state.

The Functional Unit of Septic Surgery of the Orthopaedic Surgery and Trauma Service of the Bellvitge University Hospital was appointed last February by the Interregional Council of the National Health System as one of the benchmark centres of the state in the treatment of resistant bone and joint infections.

Bellvitge Biomedical Research Institute (IDIBELL)

The Bellvitge Biomedical Research Institute (IDIBELL) is a research centre in cellular medicine, where the basic re-search of high level is at the service of relevant clinical questions and the economic development. Since March 2009 it is one of the five Spanish research centres that have been accredited as Health Research Institute by the Carlos III Health Institute.

Because of its index of excellence (27.3), the IDIBELL is at position 115 out of the 500 institutions with a best valuation of the world in all disciplines. The impact of its publications puts it among the top 10 research centres in Spain (SCIMAGO SIR World Report 2011). The IDIBELL works to do research in collaboration with the Bellvitge University Hospital, the University of Barcelona and the Catalan Institute of Oncology.

One of the researchers, Dr Manel Esteller, has received several awards and recognitions for his scientific career. These include the World Health Summit and Pfizer Award for Innovation in Biomedical Research in 2010 and the National Award in Genetics in 2011. One project of his was selected in 2009 to receive an Advanced Grant from the EU and is member of Faculty1000.

Health & Life Sciences Campus of Bellvitge of the University of Barcelona (UB)

The University of Barcelona ranks as the number one in the ranking of higher education cen-tres in Spain (SCIMAGO SIR World Report 2011). If we focus on the teaching of Life Sciences and Medicine, it has the 68th position of the World University Rankings, with the honour of being the only Spanish university that appears among the top 100 of this ranking. It was the 30th world leader in scientific production in the decade 1999-2009, according to the data of the ISI Web. The Health Sciences Campus of Bellvitge in the Biopol’H area offers degrees in Basic Medical Sciences, Nursing, Medicine, Dentistry and Podiatry.

In October 2010, the project Health University of Barcelona Campus (HUBc) achieved the recognition of Campus of International Excellence (CEI) given by the Ministry of Education and the Ministry of Science and Innovation. Therefore, the UB became the first and only general university of the country with two campuses of international excellence. The environment of the HUBC is a space that joins the potential of two cities (Barcelona and L’Hospitalet de Llobregat) from three main areas: the Health Sciences Campus of Bellvitge and Biopol of L’Hospitalet de Llobregat (Biopol’H), August Pi i Sunyer Campus (Clinical Hospital), together with the St. Joan de Déu Hospital and, finally, Zona Franca.

Institute for Bioengineering of Catalonia (IBEC)

The Institute has currently 15 research groups and 250 researchers and staff members coming from twenty different countries. Furthermore, 17 projects are funded by the European Union, six of which are funded by the Seventh Framework Programme (FP7). Today, its headquarters is located in the Barcelona Science Park but it will be moved into the Biopol’H area very soon.

The IBEC groups and their activities are organized into six research programmes:

• Cellular Biotechnology • Cellular Biomechanics and Biophysics• Nanobiotechnology • Biomaterials, implants and tissue engineering• Medical signals and instrumentation • Robotics and biomedical imaging

Comprehensive Health Consortium (CSI)

The Comprehensive Health Consortium is integrated by three hospitals –Hospital Dos de Maig, Hospital Moisès Broggi and Hospital General de L’Hospitalet- and a network of primary attention health centres.

The Minister of Health, Social Policy and Equality has awarded the Holistic Health Consortium the national prize in Innovation for the comprehensive improvement in quality care. The award recognizes CSI’s project of establishing the new management system Lean healthcare, which aims to improve and increase public safety, service quality and the satisfaction of the staff, and reduce costs too. In addition, three other projects which in-volve CSI have been selected out of the 100 Best ideas of Diario Médico.

Located in the arterial road of Gran Via in L’Hospitalet, the Biopol’H area has a Business Park that is being consoli-dated day by day. Biopol’H gathers companies of health sector, services, training and medical technology:

Biopol’H Business Park

With over 50 companies, the pharmaceutical division is present in Europe, Latin America, Central America and Asia. It is also present in food industry and chemical mar-ket. In 2012 its R&D building will begin to be built in the Biopol’H area, right next to the Duran i Reynals Hospital.

Pharmaceutical group with 100% family capital, 3,500 em-ployers, over EUR 1,000 million sales and 24 international branches. This conglomerate has its origens in an italian pharmacy, founded in 1935 by Giacomo Chiesi. Chiesi Spain has 250 employers and develops an outstanding work of R&D as well, mainly in clinical trials of phase III.

This company’s packaging solutions ensure the cold chain of thermo-sensitive products, guaranteeing customers the distribution of its products in perfect conditions -respect-ing the product’s lifetime, regardless of environmental conditions or transport conditions.

It has designed and manufactured drill holders and other com-plementary tools since 1957. Committed to innovation, one of its innovative products is a programme of stainless drill hold-ers for surgical instruments, being the only manufacturer in the world to have the ISO 13485 certification for the medical sector.

Specialized in the comissioned manufacture of medical-hospital products with CE certification and a rigorous and systematic application of the EN 13485 quality system and the DIR 93/42-DIR98/79. It has a clean room 100,000, which guarantees the rigorous perfomance of the rules of environment, health and safety.

Provides social, healthcare and mental health services both in hospitalization and day hospital. It collaborates with the Autonomous University of Barcelona, Ramon LLull University (Blanquerna Foundation) and the Red Cross in an educa-tional level. The Centre of Duran i Reynals Hospital has an allocation of 450 beds and 20 places in a Day Hospital for Neurological Diseases.

Five-star hotel, opened in 2006. It offers 280 rooms, a con-vention centre, auditorium, spa and multipurpose rooms.

Four-star hotel, designed by the Japanese architect Toyo Ito, it has been awarded as the Best sky-scraper of the world. It offers 320 rooms.

Four-star hotel, it has 160 rooms and it is mainly thought for business sector. It offers different meeting rooms and other gathering places.

Four-star hotel, it has 116 rooms and many function rooms of over 500m², specially aimed for Meetings, Incentives, Conventions and Exhibitions (MICE).

The Biopol’H Bioincubator I offers spin-off, companies and technical or consulting offices, legally constituted as a com-pany, some office space with voice and data services, meeting room, lecture hall and soon TV and videoconferencing room as well, in addition to basic cleaning, maintenance and security services. It currently has 4 companies:

The Bioincubator of Biopol’H

Besides these companies, the Bioincubator has two university groups with future spin-off projection:

Hypobaric ChamberThe Hypobaria and Biomedical Physiology Service offers specif-ic programmes to patients with breast cancer, spinal cord injury or chronic fatigue for the recovery of their physical and psychic conditions. These may include treatments of intermittent ex-posure to hypobaric hypoxia and hypoxia tolerance tests.

BarcinoIt is a project of the Centre for Thermal Spray at the University of Barcelona, which does research on new prosthesis coatings by using cold thermal spraying. This is the only group in Spain that has this “know-how”.

CAMBRA HIPOBÀRICAFISIOLOGIA DE L’EXERCICI

VCN BiosciencesThe spin-off arisen from the Virotherapy group of the Catalan Institute of Oncology is dedicated to the development of on-colytic adenovirus designed to fight tumour cells.

Zyrnat BiotherapeuticsFocused on research innovation and development of biopharmaceutical products

Adbroncus Aimed at developing new solutions, methods of diagnosis and treatment of lung conditions. The company seeks to resolve medical needs not yet covered in the respiratory market as well as in the bronchoscopy practice.

CESPUPrivate enterprise committed to research and ad-vanced training in science and health technologies.

Alliances and collaboration agreements Biopol’H is member of the Network of Science and Technology Parks of Catalonia (XPCAT), the Association of Science and Technology Parks of Spain (APTE) and the International Association of Science Parks (IASP).

CataloniaBio Association of companies which, directly or indirectly, de-velop their activities in connection with biotechnology in Catalonia, such as companies operating in other sectors but have identified potential and synergies in this field (legal consultancies, agencies, IT services and so on).

FENIN Spanish Federation of Healthcare TechnologyFounded in 1977, it includes Spanish companies in the sector to coordinate and defend their interests and represent them before the regional, national and European authorities.

AEBALL Business Association of L’Hospitalet and Baix Llobregat It is the business organization for the representation, man-agement, defence, coordination and promotion of the pro-fessional interests of the companies doing general economic activities of various sectors: industrial, commercial and ser-vices. It comprises over 3,000 companies with more than 48,000 jobs.

Barcelona Chamber of Commerce An institution that aims to ensure the promotion of the eco-nomic and business activity and the sustainable develop-ment of the territory.

Cedars-Sinai Health System A non-profit, independent healthcare organization and bio-medical research institution. With more than 2,000 physi-cians in every clinical specialty, 10,000 employees, 2,000 volunteers and 15,000 fundraising support group members.

ASBTEC Biotechnologist Association of CataloniaA non-profit entity composed by professonals, students and people related to Biotechnology, to coordinate all these agents and set up an organized collective.

Moreover, it takes part in a series of entities working to promote the economic and scientific development in the territory: